Vanguard Group
VBIO

Vanguard Group’s Valion Bio VBIO Stock Holding History

Vanguard Group’s Portfolio VBIO Stock Details VBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,822
Closed -$16.3K – 4301
2024
Q4 		$16.3K Hold
2,822
– – ﹤0.01% 4267
2024
Q3 		$12K Hold
2,822
– – ﹤0.01% 4320
2024
Q2 		$18.7K Hold
2,822
– – ﹤0.01% 4362
2024
Q1 		$60K Hold
2,822
– – ﹤0.01% 4295
2023
Q4 		$86.4K Buy
+2,822
New +$81.1K ﹤0.01% 4316
2022
Q1 		– Sell
-9
Closed -$60K – 4642
2021
Q4 		$60K Buy
+9
New +$66K ﹤0.01% 4623

Other funds holding VBIO

SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group's VBIO Position: Q1 2025 in Review

Vanguard Group sold out of Valion Bio (VBIO) in Q1 2025, closing a stake of 2,822 shares — an estimated $16.3K sold.

Vanguard Group first reported a position in VBIO in Q4 2021 and held it in 6 quarters. The position peaked at $86.4K in Q4 2023. 2 funds tracked by Wall St. Rank hold VBIO as of Q1 2025.

  • Vanguard Group reported no remaining Valion Bio position as of Q1 2025 after selling out during the quarter.
  • Vanguard Group sold 2,822 Valion Bio shares in Q1 2025, an estimated $16.3K.
  • Vanguard Group first reported a position in Valion Bio in Q4 2021 and held it in 6 quarters.
  • Vanguard Group's Valion Bio position peaked at $86.4K in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Valion Bio as of Q1 2025.

Based on Vanguard Group's 13F filing for Q1 2025, filed 9 May 2025.